Breast Cancer Specific Gene 1 is a Potential Novel Biomarker for Selected Application of Anti-Microtubule Drugs for the Treatment of Breast Cancer Patients
Abstract
Anti-microtubule drugs that cause mitotic arrest and subsequent apoptosis of cancer cells are frequently used to treat breast cancer patients with advanced or metastatic diseases. However, patient response rates to this class of chemotherapeutic agents vary significantly. Identification of cellular and genetic factors that are associated with the sensitivity to anti-microtubule drug treatment would be of great clinic implications. Our previous studies have demonstrated that the neuronal protein synuclein-gamma (SNOG), previously named BOSGI, plays oncogenic roles in breast carcinogenesis and is abnormally expressed at high levels in advanced and metastatic breast carcinomas but not expressed in normal or benign breast tissues. In this study, we show that responses of 12 breast cancer cell lines to paclitaxel-induced mitotic arrest and cytotoxicity are highly correlated with SNOG expression status. SNOG-positive cells exhibit a significant higher resistance to paclitaxel-induced mitotic arrest than SNOG-negative cells (p<0.01). Moreover, we demonstrate that down regulation of SNOG expression directly increased the effectiveness of anti-microtubule drug-induced cytotoxicity in breast cancer cells without altering cell responses to doxorubicin. These new findings suggest that SNOG expression in breast carcinomas is likely one causal factor contributing to the poor patient response to paclitaxel treatment.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2005
- Accession Number
- ADA454723
Entities
People
- Jingwen Liu